Atypical chronic myeloid leukemia (aCML) is a rare type of leukemia that is thought to arise from the uncontrolled proliferation of multipotent stem cells. It is a disease that causes the accelerated production of immature blood cells of the myeloid lineage. Typically, it occurs in the elderly who are above the age of seventy [1] [2]. Its incidence is unknown, and recorded cases show equal distribution between males and females.

The symptoms of aCML are largely the same as those found in chronic myeloid leukemia (CML), and these include anemia and its manifestations, such as pallor, dyspnea, and fatigue [1]. Furthermore, patients may present with splenomegaly or hepatomegaly [3]. Many of the symptoms are non-specific and include malaise, fever, weight loss, and headaches. More specific phenomena are easy bruising and bleeding diatheses. Some cases of aCML may be asymptomatic at the time of diagnosis.

The difference between aCML and CML is marked by certain genetic variations, notably the lack of the Philadelphia chromosome in aCML, although the two also have genetic similarities [4] [5].

Definitive diagnosis, therefore, can only be made after a peripheral blood smear and bone marrow aspirate are conducted. aCML is both myelodysplastic and myeloproliferative, producing immature cells in large numbers. In general, both bone marrow and blood samples will show elevated levels of white blood cells, granulocytes in particular [1]. As a direct result of this overproduction, bone marrow production of normal blood cells in numerous cell lineages is suppressed, leading to the aforementioned symptoms.

The survival rate for the majority of patients is less than two years [1]. Moreover, among those with aCML, up to 40% demonstrate a conversion of the disease to acute leukemia [1] [2]. A poor prognosis is marked by severe anemia, as well as a low platelet count [6]. Complications of aCML include infections, cerebral hemorrhage due to low platelets, as well as organomegaly and refractory leukocytosis [2] [3].

Diagnosis is based on laboratory studies more than clinical presentation. The two components studied are blood composition and bone marrow analysis. A peripheral smear is routinely taken, commonly revealing elevated leukocytes of more than 13 000 cells per microliter, anemia, and thrombocytopenia. White cell counts may exceed 300 000 cells per microliter [6] [7]. Upon further inspection, a proportion of these, usually less than 20%, are blast cells. The bone marrow results will show a hypercellularity as well as an elevated blast cell count. The dysplastic white cells display cytoplasmic and nucleic abnormalities, such as a pseudo Pelger-Huet anomaly and abnormal lobulation of nuclei. Distinguishing aCML from CML is done via cytogenetics, where the former does not show changes such as a Philadelphia chromosome [1].

Treatment for aCML is challenging due to its rarity and lack of targeted therapies. Options may include chemotherapy to reduce white blood cell counts and manage symptoms. In some cases, a stem cell transplant may be considered, especially for younger patients or those with a suitable donor. Supportive care, such as blood transfusions and antibiotics, is often necessary to manage complications.

The prognosis for aCML is generally poor compared to other types of leukemia. The disease tends to progress rapidly, and the median survival time is typically less than two years. However, individual outcomes can vary based on factors such as age, overall health, and response to treatment. Ongoing research aims to improve understanding and treatment of this rare condition.

The exact cause of aCML is not well understood. It is believed to result from genetic mutations that occur in the bone marrow cells, leading to uncontrolled cell growth. Unlike CML, aCML is not associated with the Philadelphia chromosome, but other genetic abnormalities may play a role. Environmental factors and family history do not appear to significantly influence the risk of developing aCML.

Atypical Chronic Myeloid Leukemia is an extremely rare condition, accounting for less than 1% of all leukemia cases. It primarily affects older adults, with most patients diagnosed in their 60s or 70s. There is no significant gender predisposition, and the disease occurs worldwide, although specific incidence rates are not well-documented due to its rarity.

In aCML, the bone marrow produces an excessive number of white blood cells, particularly myeloid cells, which are immature and dysfunctional. This overproduction disrupts the normal balance of blood cells, leading to symptoms and complications. The absence of the Philadelphia chromosome distinguishes aCML from CML, suggesting different underlying genetic mechanisms.

Currently, there are no known preventive measures for aCML due to its unclear etiology and rarity. General recommendations for maintaining overall health, such as avoiding exposure to known carcinogens and leading a healthy lifestyle, are advisable but not specific to preventing aCML.

Atypical Chronic Myeloid Leukemia is a rare and aggressive form of leukemia characterized by the overproduction of immature white blood cells. It lacks the Philadelphia chromosome, distinguishing it from typical CML. Diagnosis involves blood tests, bone marrow examination, and genetic studies. Treatment options are limited, and the prognosis is generally poor. Ongoing research is essential to improve understanding and management of this challenging condition.

If you or a loved one is diagnosed with aCML, it is important to understand that this is a rare and complex condition. Treatment may involve a combination of therapies to manage symptoms and improve quality of life. Regular follow-up with a healthcare team specializing in blood disorders is crucial. Support from family, friends, and patient advocacy groups can also be beneficial in navigating the challenges of living with aCML.

1. Orazi A, Germing U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia. 2008;22(7):1308-1319.
2. Costello R, Sainty D, Lafage-Pochitaloff M, Gabert J. Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia. Leuk Lymphoma. 1997;25(3-4):225-322.
3. Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol. 2001;19(11):2915-2926.
4. Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013;45(1):18-24.
5. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood 2013;122(25):4021-4034.
6. Hernández JM, del Cañizo MC, Cuneo A, et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol. 2000;11(4):441-444.
7. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol. 1994;87(4):746-754.